An introduction from
our management

- Chairman's Statement

- Letter from the CEO

o1
Chiesi at a Glance

02
Positive Impacts
and Challenges

- Products and Patients
~ Processes

- Global Value Chain

- Corporate Citizenship

03

Chiesi’s contribution
to the UN Sustainable
Development Goals

04
Annexes
- Impact Report
- Data, Methodology
and GRI Content Index

Company Overview: Main
Products and Therapeutic Areas

MAIN PRODUCTS (million €)

812
ep an ©)

Foster Clenil Trimbow Curosurf

 

@ Foster
(Extrafine beclomethasone
dipropionate/formoterol fumarate)

@ Clenil
(Beclomethasone Diproprionate)

@ Trimbow
(Extrafine beclomethasone
dipropionate/formoterol
fumarate/glycopyrronium bromide)

@ Corosurf
(Poractant alfa)

INVESTMENTS IN RESEARCH AND DEVELOPMENT

LS] J R C 2
among the Italian

EUROPEAN COMMISSION = Dre"mecestica

 

2th 1 3th

among the Italian among the

manufacturing European

companies pharmaceutical
companies

Source: European Commission — 2019 EU Industrial R&D Investment Scoreboard

IN 2019 CHIESI IS THE 1ST ITALIAN PHARMACEUTICAL COMPANY

IN EUROPE FOR PATENT DEPOSITS

ate iat
Poeuic tas More than

ru
eel 4 14 7
Cree) ,

Poaracied

 

 

rarer & Worldwide patents

  

in the portfolio Chiesi

~ R (12.31.2019)

 

 

 

24

Chiesi at a glance
